Co-Authors
This is a "connection" page, showing publications co-authored by Samiran Panda and Gajanan Sapkal.
Connection Strength
1.072
-
Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021 10 11; 28(7).
Score: 0.243
-
Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals. J Travel Med. 2021 10 11; 28(7).
Score: 0.243
-
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021 Jun 01; 28(4).
Score: 0.237
-
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 10 11; 28(7).
Score: 0.061
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 07; 21(7):950-961.
Score: 0.058
-
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021 03 02; 12(1):1386.
Score: 0.058
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 05; 21(5):637-646.
Score: 0.058
-
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021 Feb 19; 24(2):102054.
Score: 0.058
-
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):48-60.
Score: 0.056